相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
Mikkael A. Sekeres et al.
LEUKEMIA (2021)
Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents
Lubos Janotka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Achieving clinical success with BET inhibitors as anti-cancer agents
Tatiana Shorstova et al.
BRITISH JOURNAL OF CANCER (2021)
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies
Julia Stomper et al.
LEUKEMIA (2021)
Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia
Lu Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2021)
SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis
Edwige Voisset et al.
CANCERS (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
Salihanur Darici et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Deregulation of tumor suppressive ASXL1-PTEN/AKT axis in myeloid malignancies
Lei Cao et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2020)
Gene expression signatures associated with sensitivity to azacitidine in myelodysplastic syndromes
Kyuryung Kim et al.
SCIENTIFIC REPORTS (2020)
Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party
Ali Bazarbachi et al.
HAEMATOLOGICA (2019)
Protocol Update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0)
Huaiyu Mi et al.
NATURE PROTOCOLS (2019)
BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Fernando Vieira Pericole et al.
FRONTIERS IN ONCOLOGY (2019)
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients
Leylah M. Drusbosky et al.
BLOOD ADVANCES (2019)
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ≤ 30% blasts
G. Garcia-Manero et al.
LEUKEMIA (2017)
Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders
Kamila Polgarova et al.
ONCOTARGET (2017)
Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia
Sarah Ebinger et al.
CANCER CELL (2016)
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Guillermo Garcia-Manero et al.
LANCET ONCOLOGY (2016)
Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure
Stephanie Harel et al.
LEUKEMIA RESEARCH (2015)
Myelodysplastic Cells in Patients Reprogram Mesenchymal Stromal Cells to Establish a Transplantable Stem Cell Niche Disease Unit
Hind Medyouf et al.
CELL STEM CELL (2014)
The promise of whole-exome sequencing in medical genetics
Bahareh Rabbani et al.
JOURNAL OF HUMAN GENETICS (2014)
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
F. Traina et al.
LEUKEMIA (2014)
Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis
J. Bertacchini et al.
LEUKEMIA (2014)
Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival
Lisa Pleyer et al.
LEUKEMIA RESEARCH (2014)
Azacitidine for the treatment of patients with acute myeloid leukemia
Luca Maurillo et al.
CANCER (2012)
Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience
Murat Ozbalak et al.
HEMATOLOGICAL ONCOLOGY (2012)
5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity
N. Curik et al.
LEUKEMIA (2012)
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
L. S. Steelman et al.
LEUKEMIA (2011)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Da Wei Huang et al.
NATURE PROTOCOLS (2009)
DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis
Brad T. Sherman et al.
BMC BIOINFORMATICS (2007)
Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients
M Nyåkern et al.
LEUKEMIA (2006)
分享论文
